In these studies, each subtype exhibits distinct immune characteristics, including but not limited to tumor mutational burden (TMB), PD-1/PD-L1 levels, mismatch repair (MMR), immune checkpoint inhibitors, stromal components, and TGF-β responses. The gene discussed is CD274; the disease is neoplasm.